Validation of the Musculoskeletal Health Questionnaire in inflammatory arthritis: a psychometric evaluation.
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
28
02
2018
pubmed:
15
8
2018
medline:
24
10
2019
entrez:
15
8
2018
Statut:
ppublish
Résumé
The Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed Patient Reported Outcome Measure for use across patients with musculoskeletal conditions. This study provides a validation of the MSK-HQ examining construct validity and reliability in inflammatory arthritis. 287 adults with inflammatory arthritis completed the MSK-HQ and other Patient Reported Outcome Measures at baseline and after 3 months. Construct validity was assessed using item response theory methods. Concurrent validity was considered in relation to the HAQ and EuroQol-5D in all patients, as well as the RA Impact of Disease (RAID), PsA Impact of Disease scales, and AS Quality of Life Questionnaire (ASQoL) in disease subtypes. The MSK-HQ was approximately normally distributed with no evidence of floor or ceiling effects. A unidimensional structure was confirmed. Two items were less weakly related to the latent musculoskeletal health variable, providing some evidence of multidimensionality. Reliability was high (α = 0.93). The total score correlated highly with the HAQ (r = -0.81) and EuroQol-5D index (r = 0.80) in all patients, RAID in RA patients (r = -0.88), PsA Impact of Disease in PsA patients (r = -0.88), and ASQoL in AS patients (r = -0.86). Test-retest reliability was high (rICC = 0.73). This study provides evidence for the validity and reliability of the MSK-HQ in people with inflammatory arthritis. The major advantage of the MSK-HQ is that it is not disease specific and has high content validity in rheumatological conditions. The MSK-HQ score will be of value in clinical rheumatology practice, providing a measure that can be used across disease areas.
Identifiants
pubmed: 30107591
pii: 5069327
doi: 10.1093/rheumatology/key240
pmc: PMC6293478
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-51Subventions
Organisme : Arthritis Research UK
ID : 20518
Pays : United Kingdom
Références
J Rheumatol. 1994 Dec;21(12):2286-91
pubmed: 7699630
Arthritis Res Ther. 2012 May 30;14(3):R129
pubmed: 22647431
Qual Life Res. 2010 May;19(4):539-49
pubmed: 20169472
Arthritis Rheum. 2007 Dec 15;57(8):1358-62
pubmed: 18050173
J Clin Epidemiol. 2014 Jul;67(7):745-53
pubmed: 24582946
BMJ Open. 2016 Aug 05;6(8):e012331
pubmed: 27496243
Arthritis Rheum. 2004 Oct;50(10):3296-305
pubmed: 15476213
BMJ. 2013 Jan 28;346:f167
pubmed: 23358487
Ann Rheum Dis. 2014 Jun;73(6):1012-9
pubmed: 24790067
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Ann Rheum Dis. 2003 Jan;62(1):20-6
pubmed: 12480664
J Behav Med. 2014 Jun;37(3):524-32
pubmed: 23543315
Med Care. 2006 Nov;44(11 Suppl 3):S115-23
pubmed: 17060818
Ann Rheum Dis. 2011 Jun;70(6):1080-2
pubmed: 21378406
Arthritis Rheum. 1980 Feb;23(2):137-45
pubmed: 7362664
RMD Open. 2016 Jan 20;2(1):e000171
pubmed: 26848403
Psychol Health Med. 2012;17(4):427-39
pubmed: 22111893
J Rheumatol. 2005 Aug;32(8):1432-9
pubmed: 16078316
Value Health. 2007 Nov-Dec;10 Suppl 2:S125-37
pubmed: 17995471
Rheumatology (Oxford). 2007 Jun;46(6):904-6
pubmed: 17449488